InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,303.27
(
0.12%
)
US TECH 100
18,066.00
(
-0.07%
)
Dow Jones
40,003.59
(
0.34%
)
Brent Oil
83.76
(
0.00%
)
Bitcoin
66,958.38
(
-0.18%
)
Post# of 251852
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119659
Boards Moderated 16
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 186024

Tuesday, 09/15/2015 4:20:01 PM

Tuesday, September 15, 2015 4:20:01 PM

Post# of 251852
PTLA reports final phase-3 data on Annexa-A* in Xarelto reversal; all primary and secondary endpoints were achieved:

http://finance.yahoo.com/news/portola-pharmaceuticals-announces-second-part-120000557.html

PTLA reported the final phase-3 data from a similar trial in Eliquis reversal in Jun 2015 (#msg-114807697).

The phase-3 program for Annexa-A is now complete, but a phase-4 outcomes study is ongoing (#msg-109888826). PTLA expects to obtain FDA approval based on the phase-3 data only, but I wouldn’t consider this a certainty.

*f/k/a andexanet alfa.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up